News

CMS announced changes to how Medicare pays for primary care. Here’s 5 things to consider.

: Remembering to engage in healthy behavior can often slip to the bottom of our list of priorities. In a world where we need to be reminded and motivated to be the healthiest version of ourselves, the right nudges at the right time can help us get there.

A global phase 3 study of erenumab (Amgen and Novartis) showed that the drug was able to prevent migraines headaches.

After a successful phase 3 study, a breakthrough therapy to treat multi-drug resistant (MDR) HIV-1 is expected to launch in the United States in 2017.

Humana’s value-based reimbursement model with physicians has helped to improve care quality and health outcomes for its Medicare Advantage (MA) program members.

Here’s a three-pronged approach to improve adherence program efficiency that leverages predictive data analytics, hospital on-site pharmacies and post discharge follow-up evaluation to achieve real, measurable results.

This year’s American Society of Hematology (ASH) Conference, held in San Diego, will feature a wide array of sessions.

By addressing the root problem of obesity with structured programs, providers can help patients lose weight and very possibly avoid expensive chronic illnesses as a result. Employers and payers should incentivize healthy weight by paying for obesity care and treatment, potentially reaping substantial savings in the long term.

Creating a comprehensive customer experience doesn’t happen overnight, but the key to achieving it comes from taking a “bone deep” approach.

The results of Geneia’s year-long study – a savings of $8,375 per patient and a slowing of disease progression – demonstrate that remote patient monitoring is a wise investment for payers.

Awareness of biosimilars is high, but there are some gaps to be filled, according to a Biosimilars Forum study.

A new Express Scripts report highlights risk reporting gaps and offers advice for plans looking to close those gaps to ensure accurate risk payments

Research by Express Scripts presented at the AMCP examines costs among Medicaid members in the Florida plan to members in a similar Medicaid plan without a state-mandated formulary.

After Gilead received FDA approval for a new drug for chronic hepatitis B virus (HBV), it said low-cost, generic versions would also soon be available. That is good news for Gilead, which has been targeted by Congressional representatives for the high cost of Sovaldi and Harvoni hepatitis C treatments.

FDA granted Breakthrough Therapy Designation to brentuximab vedotin (Adcetris, Seattle Genetics) to treat patients with the most common subtypes of lymphoma.

In this commentary, Gerard J. Wedig of Simon Business School discusses the many possible implications of a Trump presidency.

Study examines the effectiveness of the Walgreens Connected Care CF program compared to a matched sample of control patients.

ACA repeal/replace was a Congressional Republican cornerstone, so there will be lots of pressure to move quickly. But that may be easier said than done.

In this commentary, the president and CEO of the Pacific Research Institute argues that Trumps victory will lead to more affordable coverage and more empowered consumers.

A new report highlights the highest uninsured rates by state. Is your state among the top 10?

Healthcare industry leaders and policy analysts discuss how the election results could impact healthcare.

Failure to report accurate data can result in significant penalties for Medicaid managed care plans.

Most Americans have health insurance today, but according to new research from Xerox, only three out of 10 are very confident that their current health plan is the best fit for their family.

U.S. congressmen last week asked the Department of Justice and the Federal Trade Commission to investigate three insulin makers for price collusion-the latest in concerns over insulin prices.

Industry leaders share their go-to strategies.

PwC report finds most primary care teams not designed to optimize care. Here’s how to mobilize non-physicians to create a care dream team.

Alcohol and drug dependency treatment goals can tied to an insurer’s pay-for-performance incentive program. Here’s how.

Lay the groundwork for bundled payment; here are three areas in which technology can play a role.